Measuring Acute Drug Demand in Humans
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Maryland, Baltimore
About this trial
This research is being done to evaluate whether suvorexant may reduce the use of, subjective liking, and demand for various drugs.
Eligibility criteria
Qualifiers
Age between 18 and 65 years old
Meets Diagnostic and Statistical Manual-5 criteria for Opioid Use Disorder (OUD) (moderate or severe)
Lifetime substance use history criterion [blinded]
Medically cleared to take suvorexant and blinded study medications
Disqualifiers
Pregnant or breast feeding
Seeking opioid use treatment
Significant mental health or physical disorder that is expected to interfere with study participation as assessed by the study physicians or medical staff
Known contraindications or allergies to suvorexant and/or the blinded study medications
Trial design
Treatments tested in this trial
- Drug A (Blinded Drug)
- Drug B (Blinded Drug)
- Drug C (Blinded Drug)
- Drug D (Blinded Drug)
- Suvorexant (20mg/day)
- Placebo
Treatment groups
75 Participants
are divided into 2 treatment groupsLocations
1General Clinical Research Center21201, BaltimoreMaryland, United States
Sponsors and collaborators
University of Maryland, Baltimore
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Source ClinicalTrials.gov